In February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of my favorite stocks. Shares have jumped by more than 20,000% since then.

I believe we are about to do it again with this new AI project called Stargate

Jeffrey V. Poulton net worth and biography

Jeffrey Poulton Biography and Net Worth

CFO of Alnylam Pharmaceuticals

Jeffrey Poulton is appointed as Chief Financial Officer, Executive Vice President of the Company, effective August 13, 2019. Mr. Poulton was most recently Chief Financial Officer of Indigo Ag, Inc., a company dedicated to harnessing nature to help farmers sustainably feed the planet. Prior to that Mr. Poulton was Chief Financial officer of Shire plc, and member of Shire's Executive Committee and Board of Directors. As CFO of Shire, he had responsibility for all aspects of the finance organization including SEC reporting, Treasury, Tax, Internal Audit, Financial Planning & Analysis, Investor Relations, and Procurement. Prior to his CFO role at Shire he held a variety of financial roles and also served in a general management capacity while leading Shire's rare disease commercial operations in North America, Latin America, and Asia Pacific. Prior to his fifteen-year tenure at Shire, Jeff led corporate finance and business development initiatives in both the energy and materials manufacturing sectors, in financial leadership positions at Cinergy Corp and PPG industries. He also served as a U.S. Navy Commissioned Officer. Mr. Poulton holds a B.A. in Economics from Duke University and an MBA in Finance from the Kelly School of Business at Indiana University. He is a member of the Board of Directors of EIP Pharmaceuticals.

What is Jeffrey V. Poulton's net worth?: The estimated net worth of Jeffrey V. Poulton is at least $7.08 million as of June 25th, 2024. Mr. Poulton owns 28,892 shares of Alnylam Pharmaceuticals stock worth more than $7,075,362 as of November 23rd. This net worth estimate does not reflect any other assets that Mr. Poulton may own. Additionally, Mr. Poulton receives a salary of $1,050,000.00 as CFO at Alnylam Pharmaceuticals. Learn More about Jeffrey V. Poulton's net worth.
How old is Jeffrey V. Poulton?: Mr. Poulton is currently 56 years old. There are 5 older executives and no younger executives at Alnylam Pharmaceuticals. The oldest executive at Alnylam Pharmaceuticals is Dr. Yvonne L. Greenstreet M.B.A., MBChB, CEO & Director, who is 61 years old. Learn More on Jeffrey V. Poulton's age.
What is Jeffrey V. Poulton's salary?: As the CFO of Alnylam Pharmaceuticals, Inc., Mr. Poulton earns $1,050,000.00 per year. There are 3 executives that earn more than Mr. Poulton. The highest earning executive at Alnylam Pharmaceuticals is Dr. Yvonne L. Greenstreet M.B.A., MBChB, CEO & Director, who commands a salary of $2,150,000.00 per year. Learn More on Jeffrey V. Poulton's salary.
How do I contact Jeffrey V. Poulton?: The corporate mailing address for Mr. Poulton and other Alnylam Pharmaceuticals executives is 675 WEST KENDALL STREET HENRI A. TERMEER SQUARE, CAMBRIDGE MA, 02142. Alnylam Pharmaceuticals can also be reached via phone at (617) 551-8200 and via email at [email protected]. Learn More on Jeffrey V. Poulton's contact information.
Has Jeffrey V. Poulton been buying or selling shares of Alnylam Pharmaceuticals?: Jeffrey V. Poulton has not been actively trading shares of Alnylam Pharmaceuticals over the course of the past ninety days. Most recently, Jeffrey V. Poulton sold 1,605 shares of the business's stock in a transaction on Tuesday, June 25th. The shares were sold at an average price of $231.00, for a transaction totalling $370,755.00. Following the completion of the sale, the chief financial officer now directly owns 28,892 shares of the company's stock, valued at $6,674,052. Learn More on Jeffrey V. Poulton's trading history.
Who are Alnylam Pharmaceuticals' active insiders?: Alnylam Pharmaceuticals' insider roster includes Dennis Ausiello (Director), Michael Bonney (Director), Jeffrey Dunn (CEO), Kevin Fitzgerald (EVP), Indrani Franchini (EVP), Pushkal Garg (CMO), Yvonne Greenstreet (COO), Laurie Keating (EVP), John Maraganore (CEO), Steven Paul (Director), Jeffrey Poulton (CFO), David Pyott (Director), Amy Schulman (Director), Phillip Sharp (Director), Tolga Tanguler (EVP), and Akshay Vaishnaw (Insider). Learn More on Alnylam Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Alnylam Pharmaceuticals?: In the last year, insiders at the biopharmaceutical company sold shares 11 times. They sold a total of 154,848 shares worth more than $34,733,444.48. The most recent insider tranaction occured on August, 20th when CEO Yvonne Greenstreet sold 15,000 shares worth more than $4,200,000.00. Insiders at Alnylam Pharmaceuticals own 1.5% of the company. Learn More about insider trades at Alnylam Pharmaceuticals.
Information on this page was last updated on 8/20/2024.

Jeffrey V. Poulton Insider Trading History at Alnylam Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
6/25/2024	Sell	1,605	$231.00	$370,755.00	28,892
8/4/2023	Sell	3,460	$185.85	$643,041.00	15,873
4/27/2023	Sell	977	$194.59	$190,114.43	11,706

Jeffrey V. Poulton Buying and Selling Activity at Alnylam Pharmaceuticals

Alnylam Pharmaceuticals Company Overview

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Today's Range

Now: $244.89

$243.35

$248.90

50 Day Range

MA: $273.54

$232.27

$300.55

2 Week Range

Now: $244.89

$141.98

$304.39

Volume

525,884 shs

Average Volume

876,685 shs

Market Capitalization

$31.59 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.39

Bill Gates’s Next Big AI Bet: Stargate

From Brownstone Research | Ad

In February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of my favorite stocks. Shares have jumped by more than 20,000% since then.

I believe we are about to do it again with this new AI project called Stargate

Jeffrey Poulton Biography and Net Worth

What is Jeffrey V. Poulton's net worth?

How old is Jeffrey V. Poulton?

What is Jeffrey V. Poulton's salary?

How do I contact Jeffrey V. Poulton?

Has Jeffrey V. Poulton been buying or selling shares of Alnylam Pharmaceuticals?

Who are Alnylam Pharmaceuticals' active insiders?

Are insiders buying or selling shares of Alnylam Pharmaceuticals?